Operaciones BioMarin Pharmaceutical Inc - BMRN CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.88 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
Horario tarifa nocturna | 22:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Cierre previo* | 112.62 |
Abrir* | 112.65 |
Cambio de 1 año* | 27.63% |
Rango del día* | 111.69 - 113.28 |
Rango de 52 semanas | 70.73-117.77 |
Volumen medio (10 días) | 1.46M |
Volumen medio (3 meses) | 31.05M |
Capitalización de mercado | 20.85B |
Ratio P/E | 284.19 |
Acciones en circulación | 185.85M |
Ingresos | 2.01B |
EPS | 0.39 |
Dividendo (Rendimiento %) | N/A |
Beta | 0.36 |
Próxima fecha de resultados | Feb 21, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 111.72 | -0.63 | -0.56% | 112.35 | 113.68 | 111.21 |
Feb 2, 2023 | 112.62 | -3.05 | -2.64% | 115.67 | 116.34 | 111.50 |
Feb 1, 2023 | 116.50 | 2.14 | 1.87% | 114.36 | 116.68 | 113.19 |
Jan 31, 2023 | 115.12 | 1.18 | 1.04% | 113.94 | 115.38 | 113.94 |
Jan 30, 2023 | 114.47 | -1.80 | -1.55% | 116.27 | 116.93 | 114.14 |
Jan 27, 2023 | 116.79 | 1.47 | 1.27% | 115.32 | 117.56 | 115.32 |
Jan 26, 2023 | 116.58 | 1.07 | 0.93% | 115.51 | 116.94 | 114.46 |
Jan 25, 2023 | 115.45 | 1.60 | 1.41% | 113.85 | 116.29 | 113.84 |
Jan 24, 2023 | 113.39 | 3.30 | 3.00% | 110.09 | 113.79 | 110.09 |
Jan 23, 2023 | 110.98 | 1.71 | 1.56% | 109.27 | 111.38 | 108.74 |
Jan 20, 2023 | 110.47 | 1.35 | 1.24% | 109.12 | 110.86 | 108.49 |
Jan 19, 2023 | 108.78 | -1.10 | -1.00% | 109.88 | 109.96 | 108.60 |
Jan 18, 2023 | 110.28 | -0.81 | -0.73% | 111.09 | 111.73 | 110.15 |
Jan 17, 2023 | 111.36 | 0.36 | 0.32% | 111.00 | 112.79 | 109.88 |
Jan 13, 2023 | 112.27 | 1.12 | 1.01% | 111.15 | 114.58 | 110.75 |
Jan 12, 2023 | 112.91 | 2.89 | 2.63% | 110.02 | 113.43 | 108.97 |
Jan 11, 2023 | 110.68 | -0.47 | -0.42% | 111.15 | 112.46 | 108.79 |
Jan 10, 2023 | 110.79 | 3.99 | 3.74% | 106.80 | 111.79 | 106.11 |
Jan 9, 2023 | 106.58 | -2.13 | -1.96% | 108.71 | 109.86 | 105.28 |
Jan 6, 2023 | 108.31 | 2.12 | 2.00% | 106.19 | 109.07 | 106.19 |
BioMarin Pharmaceutical Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos totales | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Ingresos | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Coste de los ingresos, total | 209.62 | 241.786 | 315.264 | 359.466 | 524.272 | 470.515 |
Beneficio bruto | 907.234 | 1071.86 | 1175.95 | 1344.58 | 1336.18 | 1375.76 |
Gastos totales de explotación | 1920.28 | 1328.35 | 1614.74 | 1804.51 | 1897.22 | 1928.62 |
Gastos de venta/general/administración Gastos, total | 472.976 | 565.167 | 610.014 | 675.665 | 737.784 | 760.923 |
Investigación y desarrollo | 661.905 | 610.753 | 696.328 | 715.007 | 628.116 | 628.793 |
Depreciation / Amortization | 30.2 | 36.2 | 30.3 | 53.5 | 62.2 | 61.9 |
Gasto (ingreso) por intereses - Explotación neta | 3.617 | -10.831 | -5.661 | 5.259 | -0.115 | -1.548 |
Gastos (ingresos) extraordinarios | 599.118 | -125 | -50 | -25 | -59.495 | 0 |
Other Operating Expenses, Total | -57.153 | 10.271 | 18.491 | 20.608 | 4.458 | 8.033 |
Ingresos de explotación | -803.429 | -14.7 | -123.524 | -100.457 | -36.765 | -82.341 |
Ingresos por intereses (gastos), netos No operativos | -32.55 | -29.145 | -21.386 | -1.299 | -12.705 | -4.855 |
Otros, netos | 4.929 | 7.97 | 2.205 | 6.945 | 7.148 | 11.846 |
Ingresos netos antes de impuestos | -831.05 | -35.875 | -142.705 | -94.811 | -42.322 | -75.35 |
Ingresos netos después de impuestos | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Beneficio neto antes de partidas extra. Elementos | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Ingresos netos | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Beneficio neto diluido | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Promedio ponderado de acciones diluidas | 165.985 | 174.427 | 177.061 | 179.039 | 191.678 | 182.852 |
BPA diluido sin partidas extraordinarias | -3.79679 | -0.4285 | -0.43607 | -0.1332 | 0.0238 | -0.37189 |
BPA normalizado diluido | -1.45063 | -0.89431 | -0.61962 | -0.22396 | -0.17796 | -0.37189 |
Total de partidas extraordinarias | -42.3 | 0 | 854.539 | 3.92 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Ingresos totales | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Ingresos | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Coste de los ingresos, total | 120.166 | 127.062 | 103.537 | 119.75 | 116.965 |
Beneficio bruto | 365.864 | 374.631 | 305.205 | 330.06 | 402.394 |
Gastos totales de explotación | 460.944 | 490.021 | 461.961 | 515.69 | 382.032 |
Gastos de venta/general/administración Gastos, total | 174.318 | 184.161 | 183.333 | 217.563 | 194.619 |
Investigación y desarrollo | 148.725 | 161.107 | 157.869 | 161.092 | 160.836 |
Depreciation / Amortization | 15.4 | 15.5 | 15.4 | 15.6 | 15.6 |
Gastos (ingresos) extraordinarios | 0 | 0 | 0 | 0 | -108 |
Other Operating Expenses, Total | 2.335 | 2.191 | 1.822 | 1.685 | 2.012 |
Ingresos de explotación | 25.086 | 11.672 | -53.219 | -65.88 | 137.327 |
Ingresos por intereses (gastos), netos No operativos | -2.716 | 0.479 | -1.866 | -0.752 | -1.986 |
Otros, netos | 0.858 | 2.005 | 8.925 | 0.058 | -1.154 |
Ingresos netos antes de impuestos | 23.228 | 14.156 | -46.16 | -66.574 | 134.187 |
Ingresos netos después de impuestos | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Beneficio neto antes de partidas extra. Elementos | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Ingresos netos | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Beneficio neto diluido | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Promedio ponderado de acciones diluidas | 184.365 | 185.427 | 183.214 | 183.56 | 194.886 |
BPA diluido sin partidas extraordinarias | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.61984 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.12096 |
Total de partidas extraordinarias | 3.92 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Activo Corriente | 1421.79 | 2207.14 | 2056.22 | 1942.14 | 2342.22 | 2274.39 |
Efectivo e inversiones a corto plazo | 789.677 | 1395.97 | 1084.31 | 753.807 | 1065.39 | 1013.88 |
Efectivo y Equivalentes | 408.33 | 598.028 | 493.982 | 437.446 | 649.158 | 587.276 |
Inversiones a corto plazo | 381.347 | 797.94 | 590.326 | 316.361 | 416.228 | 426.599 |
Total deudores, neto | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Accounts Receivable - Trade, Net | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Total Inventory | 355.126 | 475.775 | 530.871 | 680.275 | 698.548 | 776.669 |
Other Current Assets, Total | 61.708 | 74.036 | 98.403 | 130.657 | 129.934 | 110.442 |
Total Assets | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Property/Plant/Equipment, Total - Net | 798.768 | 896.7 | 948.682 | 1070.3 | 1089.58 | 1081.88 |
Property/Plant/Equipment, Total - Gross | 1141.36 | 1303.43 | 1421.32 | 1619.4 | 1725.18 | 1802.45 |
Accumulated Depreciation, Total | -342.594 | -406.734 | -472.635 | -549.1 | -635.595 | -720.574 |
Goodwill, Net | 197.039 | 197.039 | 197.039 | 197.039 | 196.199 | 196.199 |
Intangibles, Net | 553.78 | 517.51 | 491.808 | 456.58 | 417.271 | 388.652 |
Long Term Investments | 572.711 | 385.785 | 235.864 | 411.978 | 285.473 | 507.793 |
Other Long Term Assets, Total | 479.601 | 428.947 | 497.52 | 611.997 | 1517.28 | 1554.42 |
Total Current Liabilities | 439.31 | 816.518 | 523.241 | 932.503 | 492.548 | 539.822 |
Payable/Accrued | 198.53 | 161.652 | 208.119 | 240.981 | 191.429 | 193.003 |
Accrued Expenses | 158.926 | 201.601 | 213.03 | 287.878 | 266.254 | 277.059 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 22.478 | 360.949 | 0 | 365.131 | 2.865 | 2.266 |
Other Current Liabilities, Total | 59.376 | 92.316 | 102.092 | 38.513 | 32 | 67.494 |
Total Liabilities | 1257.42 | 1824.46 | 1459.19 | 1567.66 | 1742.02 | 1732.58 |
Total Long Term Debt | 660.761 | 813.521 | 830.417 | 492.946 | 1079.15 | 1081.04 |
Long Term Debt | 660.761 | 813.521 | 830.417 | 486.238 | 1075.15 | 1079.08 |
Deferred Income Tax | 0 | |||||
Other Liabilities, Total | 157.344 | 194.423 | 105.53 | 142.209 | 170.319 | 111.726 |
Total Equity | 2766.27 | 2808.66 | 2967.94 | 3122.38 | 4106 | 4270.74 |
Common Stock | 0.173 | 0.176 | 0.178 | 0.18 | 0.182 | 0.184 |
Additional Paid-In Capital | 4288.11 | 4483.22 | 4669.93 | 4832.71 | 4993.41 | 5191.5 |
Retained Earnings (Accumulated Deficit) | -1520.51 | -1637.55 | -1694.13 | -1720.71 | -861.609 | -925.689 |
Other Equity, Total | -1.505 | -34.463 | -6.113 | 6.638 | -29.867 | 6.116 |
Total Liabilities & Shareholders’ Equity | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Total Common Shares Outstanding | 172.648 | 175.844 | 178.253 | 179.838 | 181.741 | 183.913 |
Unrealized Gain (Loss) | -2.722 | -1.917 | 3.565 | 3.889 | -1.373 | |
Capital Lease Obligations | 6.708 | 4.006 | 1.96 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 2288.77 | 2357.84 | 2311.57 | 2274.39 | 2394.02 |
Efectivo e inversiones a corto plazo | 1087.49 | 1123.4 | 1079.48 | 1013.88 | 1056.24 |
Efectivo y Equivalentes | 667.313 | 641.533 | 617.143 | 587.276 | 605.44 |
Inversiones a corto plazo | 420.178 | 481.864 | 462.333 | 426.599 | 450.798 |
Total deudores, neto | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Accounts Receivable - Trade, Net | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Total Inventory | 713.929 | 710.975 | 749.406 | 776.669 | 786.356 |
Other Current Assets, Total | 91.249 | 99.046 | 107.751 | 110.442 | 121.283 |
Total Assets | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Property/Plant/Equipment, Total - Net | 1022.47 | 1026.58 | 1024.79 | 1035.46 | 1039.54 |
Property/Plant/Equipment, Total - Gross | 1679.77 | 1704.7 | 1724.7 | 1756.04 | 1780.71 |
Accumulated Depreciation, Total | -657.296 | -678.126 | -699.915 | -720.574 | -741.167 |
Goodwill, Net | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
Intangibles, Net | 405.903 | 394.298 | 388.487 | 388.652 | 374.251 |
Long Term Investments | 321.127 | 350.237 | 466.618 | 507.793 | 462.827 |
Other Long Term Assets, Total | 1570.58 | 1573.35 | 1589.81 | 1600.83 | 1595.86 |
Total Current Liabilities | 430.035 | 443.344 | 514.898 | 539.822 | 490.418 |
Payable/Accrued | 165.001 | 176.073 | 203.321 | 203.467 | 187.81 |
Accrued Expenses | 209.203 | 207.005 | 241.535 | 268.861 | 214.435 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 55.831 | 60.266 | 70.042 | 67.494 | 88.173 |
Total Liabilities | 1643.04 | 1656.93 | 1711.33 | 1732.58 | 1671.39 |
Total Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Other Liabilities, Total | 136.881 | 136.471 | 118.335 | 113.686 | 100.913 |
Total Equity | 4162.01 | 4241.57 | 4266.15 | 4270.74 | 4391.31 |
Common Stock | 0.183 | 0.183 | 0.184 | 0.184 | 0.185 |
Additional Paid-In Capital | 5010.62 | 5083.83 | 5133.74 | 5191.5 | 5206.29 |
Retained Earnings (Accumulated Deficit) | -844.238 | -831.297 | -867.791 | -925.689 | -804.891 |
Unrealized Gain (Loss) | 2.387 | 1.821 | 1.218 | -1.373 | -9.264 |
Other Equity, Total | -6.941 | -12.967 | -1.204 | 6.116 | -1.002 |
Total Liabilities & Shareholders’ Equity | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Total Common Shares Outstanding | 182.671 | 183.322 | 183.567 | 183.913 | 184.902 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos netos/Línea de salida | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Efectivo de actividades de explotación | -227.837 | -8.757 | 20.208 | 48.262 | 85.365 | 304.536 |
Efectivo de actividades de explotación | 96.912 | 87.861 | 95.671 | 105.3 | 105.172 | 108.039 |
Deferred Taxes | -228.054 | 44.464 | -68.378 | -82.76 | -888.907 | -15.608 |
Partidas no monetarias | 693.791 | 69.923 | 119.546 | 150.662 | 234.417 | 210.151 |
Cash Taxes Paid | 95.857 | 23.895 | 16.676 | 9.726 | 8.977 | 18.153 |
Intereses pagados en efectivo | 8.643 | 8.544 | 11.623 | 8.552 | 12.178 | 10.395 |
Cambios en el capital circulante | -160.276 | -93.963 | -49.42 | -101.092 | -224.417 | 66.034 |
Efectivo de actividades de inversión | -484.047 | -305.459 | 264.351 | -31.026 | -53.621 | -366.313 |
Gastos de capital | -148.38 | -199.219 | -144.62 | -163.406 | -137.519 | -119.225 |
Otras partidas de flujo de caja de inversión, total | -335.667 | -106.24 | 408.971 | 132.38 | 83.898 | -247.088 |
Efectivo procedente de actividades de financiación | 727.108 | 507.145 | -388.007 | -74.674 | 181.118 | -0.048 |
Elementos de flujo de caja de financiación | -60.057 | -35.427 | -80.542 | -101.198 | -44.638 | -46.203 |
Emisión (retiro) de acciones, neto | 787.165 | 60.859 | 67.488 | 31.611 | 21.913 | 49.194 |
Efectos del cambio de divisas | -3.934 | -3.231 | -0.598 | 0.902 | -1.15 | -0.057 |
Variación neta de la tesorería | 11.29 | 189.698 | -104.046 | -56.536 | 211.712 | -61.882 |
Emisión (amortización) de deuda, neta | 481.713 | -374.953 | -5.087 | 203.843 | -3.039 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 17.371 | 30.312 | -6.182 | -64.08 | 120.798 |
Cash From Operating Activities | 113.512 | 196.296 | 293.356 | 304.536 | -45.431 |
Cash From Operating Activities | 27.983 | 55.214 | 82.053 | 108.039 | 27.343 |
Deferred Taxes | 3.335 | 1.204 | -12.02 | -15.608 | 4.8 |
Non-Cash Items | 56.553 | 111.414 | 163.355 | 210.151 | -61.68 |
Cash Taxes Paid | 2.998 | 10.159 | 15.531 | 18.153 | 1.316 |
Cash Interest Paid | 1.465 | 5.195 | 6.673 | 10.395 | 1.422 |
Changes in Working Capital | 8.27 | -1.848 | 66.15 | 66.034 | -136.692 |
Cash From Investing Activities | -70.788 | -191.045 | -310.892 | -366.313 | 87.782 |
Capital Expenditures | -28.254 | -54.506 | -74.866 | -119.225 | -30.675 |
Other Investing Cash Flow Items, Total | -42.534 | -136.539 | -236.026 | -247.088 | 118.457 |
Cash From Financing Activities | -24.364 | -13.413 | -14.444 | -0.048 | -25.28 |
Financing Cash Flow Items | -29.097 | -39.112 | -44.829 | -46.203 | -32.949 |
Issuance (Retirement) of Stock, Net | 5.817 | 27.64 | 32.877 | 49.194 | 8.235 |
Issuance (Retirement) of Debt, Net | -1.084 | -1.941 | -2.492 | -3.039 | -0.566 |
Foreign Exchange Effects | -0.205 | 0.537 | -0.035 | -0.057 | 1.093 |
Net Change in Cash | 18.155 | -7.625 | -32.015 | -61.882 | 18.164 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
PRIMECAP Management Company | Investment Advisor | 9.4838 | 17625505 | -52980 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.1613 | 17026106 | 263453 | 2022-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 7.9494 | 14773963 | -233100 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3137 | 9875458 | 113895 | 2022-09-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 4.1004 | 7620494 | 0 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 3.0607 | 5688259 | 129970 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8402 | 5278438 | -117928 | 2022-09-30 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.7437 | 5099164 | 46571 | 2022-09-30 | MED |
Capital Research Global Investors | Investment Advisor | 2.6563 | 4936740 | 1394 | 2022-09-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 2.2221 | 4129724 | -71509 | 2022-09-30 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 1.9131 | 3555555 | 271555 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.353 | 2514523 | 42707 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.2642 | 2349540 | 223693 | 2021-12-31 | LOW |
Parnassus Investments, LLC | Investment Advisor | 1.2583 | 2338529 | -227551 | 2022-12-31 | LOW |
Barclays Bank PLC | Investment Advisor | 1.1309 | 2101767 | 182659 | 2022-09-30 | MED |
Palo Alto Investors LP | Hedge Fund | 1.0634 | 1976265 | -85108 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.0085 | 1874272 | 348269 | 2022-09-30 | HIGH |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.9306 | 1729432 | 1607478 | 2022-09-30 | HIGH |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 0.924 | 1717310 | 17600 | 2022-09-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7732 | 1437057 | -102057 | 2022-09-30 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com GroupTraders
Clientes activos mensualmente
Volumen mensual de inversión
Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
Sobre BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical, Inc. a una Compañía biotecnológica. La Compañía desarrolla y comercializa productos farmacéuticos para varias enfermedades y afecciones medicas. A 31 de Diciembre de 2016, el porfolio de terapias de la compañía consistía en cinco productos y múltiples candidatos para productos clínicos y preclínicos. Sus productos comerciales incluye Aldurazyme (laronidase) para Mucopolysaccharidosis I (MPS I), Firdapse (fosfato de amifampridina) para el Síndrome miasténico de Lambert Eaton (LEMS), Kuvan (dihidrocloruro de sapropterina) para fenilcetonuria (PKU), Naglazyme (galsulfasa) para Mucopolisacáridos MPS para Mucopolisacáridos VI (MPS VI) y Vimizim (elosulfase alfa) para Mucopolisacáridos IV Tipo A (MPS IV A). La Compañía está realizando ensayos clínicos de varios productos candidatos para el tratamiento de diversas enfermedades. Sus candidatos a productos clínicos incluye Brineura, pegvaliase, vosoritide, BMN 270 y BMN 250.
- IndustriaBiopharmaceuticals
- Dirección105 Digital Dr, NOVATO, CA, United States (USA)
- Empleados3045
- CEOJean-Jacques Bienaime
Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 485.000 traders de todo el mundo que eligen operar con Capital.com